Appendix B

Speaker Biographical Sketches

Helen M. Blau, Ph.D., is the Donald E. and Delia B. Baxter Foundation professor and director of the Baxter Laboratory for Stem Cell Biology at Stanford University. Blau’s research area is regenerative medicine with a focus on stem cells. She is world renowned for her work on nuclear reprogramming and demonstration of the plasticity of cell fate using cell fusion. Blau led the field with novel approaches to treating muscle damaged due to disease, injury, or aging. She pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Her laboratory discovered that transient exposure to prostaglandin E2 rejuvenates muscle stem cell function long term, enhancing muscle repair. She identified a novel hallmark of aging, the prostaglandin degrading enzyme, 15-PGDH, and showed that its inhibition augments aged muscle mass and strength. Blau served as president of the American Society for Developmental Biology, president of the International Society for Differentiation, and member of the Harvard University Board of Overseers. She is an elected member of the American Institute for Medical and Biological Engineering, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the National Academy of Medicine, and the National Academy of Sciences.

Edward Botchwey, Ph.D., is an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University. His research focuses on the delivery of naturally occurring small molecules and synthetic derivatives for applications in tissue engineering and regenerative medicine. He is particularly

interested in how transient control of immune response using bioactive lipids can be exploited to control trafficking of stem cells, enhance tissue vascularization, and resolve inflammation. Dr. Botchwey received both ME and Ph.D. degrees in materials science engineering and bioengineering from the University of Pennsylvania in 1998 and 2002, respectively. He was recruited to the faculty at Georgia Tech in 2012. Dr. Botchwey is a former Ph.D. fellow of the National GEM Consortium, a former postdoctoral fellow of the UNCF-Merk Science Initiative, and a recipient of the Presidential Early Career Awards for Scientists and Engineers from the National Institutes of Health. Dr. Botchwey also serves on the Board of Directors of the Biomedical Engineering Society (BMES) and serves as the secretary to the Biomedical Engineering Decade committee.

Danielle Brooks, Ph.D., is a pharmacology/toxicology reviewer in the Office of Tissues and Advanced Therapies (OTAT). She received her Ph.D. in biomedical sciences with a concentration in cancer and developmental biology at the University of Tennessee Health Science Center in Memphis. Following her graduate training, Dr. Brooks completed her postdoctoral training in the Women’s Malignancies Branch of the National Cancer Institute. In 2017 she joined the NCI–FDA Interagency Oncology Task Force Fellowship program as a product quality research/review fellow in the Cellular and Tissues Therapies Branch of OTAT. At the completion of her fellowship, Dr. Brooks joined the Pharmacology/Toxicology Branch, where she now focuses on the review of preclinical toxicology and pharmacology data to support the safety of cell and gene therapies, tissue-engineered products, devices, and combination products.

Jennifer H. Elisseeff, Ph.D., is the Morton F. Goldberg Endowed Professor of ophthalmology and a professor of orthopaedic surgery at the Johns Hopkins School of Medicine. She is the Jules Stein Professor of ophthalmology and also holds appointments in the Johns Hopkins Department of Chemical and Biological Engineering and the Department of Materials Science and Engineering. Dr. Elisseeff is the director of the Translational Tissue Engineering Center, where she and her team of scientists are engaged in engineering technologies to repair lost tissues and are using biomaterials to develop a synthetic cornea. Dr. Elisseeff received a Ph.D. in medical engineering from the Harvard–MIT Division of Health Sciences and Technology. After doctoral studies Dr. Elisseeff was a fellow at the National Institute of General Medical Sciences Pharmacology Research Associate Program, where she worked in the National Institute of Dental and Craniofacial Research. She joined the Johns Hopkins faculty in 2001. In 2004 Elisseeff cofounded Cartilix, Inc., a startup that translated adhesive and biomaterial technologies for treating orthopedic disease, acquired by

Biomet (now Zimmer Biomet) in 2009. In 2009 she also founded Aegeria Soft Tissue and Tissue Repair, startups focused on soft tissue regeneration and wound healing. She serves on the Scientific Advisory Boards of Bausch and Lomb, Kythera Biopharmaceutical, and Cellular Bioengineering, Inc. Dr. Elisseeff has received awards including the Carnegie Mellon Young Alumni Award, the Arthritis Investigator Award from the Arthritis Foundation, and the Yasuda Award from the Society of Physical Regulation in Medicine and Biology. She was recognized by Technology Review magazine as a top innovator under 35 in 2002 and was included with the top 10 technologies to change the future. In 2008 Dr. Elisseeff was elected a fellow in the American Institute for Medical and Biological Engineering and a Young Global Leader in the World Economic Forum. In 2018 Dr. Elisseeff was elected to both the National Academy of Medicine and the National Academy of Engineering. She was the 2019 recipient of the NIH Director’s Pioneer Award.

Sherilyn George-Clinton is a leader and collaborator with the Multiple Sclerosis: You Are Not Alone (M.S. Y.A.N.A) organization and a science writer for The NeuroLeadership. The NeuroLeadership is a global research organization that partners with organizations to develop their leaders and transform their cultures. Ms. George-Clinton helps create content to reach customers and prospects with the practical application of their research in performance; culture and leadership; and diversity, equity, and inclusion. As a freelance writer, Ms. George-Clinton communicates with or about patients using diverse means, working to convey technical information with nontechnical people without talking down to them and fostering engagement through storytelling. Ms. George-Clinton received her BA in English from Denison University.

George Hajishengallis, D.D.S., Ph.D., earned a DDS from the University of Athens (1989) and a Ph.D. in microbiology/immunology from the University of Alabama at Birmingham (1994). He is currently the Thomas W. Evans Centennial Professor at the University of Pennsylvania, School of Dental Medicine, Department of Basic and Translational Sciences. His field of interest is the host–microbe interface, and his work has illuminated novel mechanisms of microbial dysbiosis and inflammation as well as inflammation resolution and tissue regeneration. A current focus of his laboratory involves the immunometabolic regulation of trained myelopoiesis and its effects on health and disease. He combines basic and translational research leading to innovative approaches to clinical problems, such as exemplified by periodontitis, where his preclinical work has recently led to a phase 2a clinical trial in patients with periodontal inflammation (successfully treated with a complement C3 inhibitor; AMY-101). He has published more than

210 papers (with over 24,000 citations), including in Cell, Nature Immunology, Science Translational Medicine, the Journal of Clinical Investigation, Cell Host & Microbe, PNAS, The New England Journal of Medicine, and Nature Reviews Immunology. He received the IADR Distinguished Scientist Award in Oral Biology in 2012 and the NIH/NIDCR MERIT Award in 2016. He was named Highly Cited Researcher (Clarivate/Web-of-Science) in 2018 and 2020.

Robert Jenq, M.D., is the deputy department chair and an associate professor in the Department of Genomic Medicine and an associate professor in the Department of Stem Cell Transplantation at the University of Texas MD Anderson Cancer Center. His career aim is to develop and evaluate strategies that improve outcomes after hematopoietic stem cell transplantation (HSCT), in particular by augmenting graft-versus-tumor (GVT) to reduce the rates of malignant relapse and alleviating graft-versus-host disease (GVHD). To this goal, he has studied therapies that modulate alloreactive T cells in GVT and GVHD, using mouse models of HSCT. To develop strategies of augmenting antitumor immunity following HSCT, he has focused in particular on T-cell repertoire enhancement strategies. Simultaneously, he has begun to study the T-cell repertoire in the setting of GVHD. Finally, he has also examined how aspects of mucosal immunology can impact intestinal GVHD, including the microbial flora and dietary factors.

James L. Kirkland, M.D., Ph.D., is the director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic and Noaber Foundation Professor of Aging Research. Dr. Kirkland’s research is on the contribution of fundamental aging processes, particularly cellular senescence, to age-related and chronic diseases and development of agents and strategies for targeting fundamental aging mechanisms to treat age- and chronic disease–related conditions. Additional research areas include molecular and physiological mechanisms of age-related adipose tissue and metabolic dysfunction, frailty, and loss of resilience to infections and acute diseases in old age. Dr. Kirkland’s laboratory published the first article about agents that selectively eliminate senescent cells—senolytic drugs. Dr. Kirkland demonstrated that senolytic agents enhance healthspan and delay, prevent, or alleviate multiple age-related disorders and diseases in mouse models. He published the first clinical trials of senolytic drugs. He is preparing or conducting clinical studies of senolytics, including for COVID-19, frailty in elderly women, Alzheimer’s disease, diabetes/obesity, osteoporosis, childhood cancer survivors, restoring function of organs from old donors to enable transplantation, idiopathic pulmonary fibrosis, preeclampsia, and others. He has more than 225 publications and holds over 50 patents. Dr. Kirkland is principal investigator of the Translational Geroscience Network (R33 AG061456),

which brings together eight academic institutions to translate healthspan interventions, including senolytics and other drugs that target fundamental aging processes, from bench to bedside. He is a scientific advisory board member for several companies and academic organizations. He is president of the American Federation for Aging Research, a past member of the National Advisory Council on Aging of the National Institutes of Health, past chair of the Biological Sciences Section of the Gerontological Society of America, and past member of the Clinical Trials Advisory Panel of the National Institute on Aging. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism. Dr. Kirkland is the 2020 recipient of the Irving S. Wright Award of Distinction from the American Federation for Aging Research.

Katarina Le Blanc, M.D., Ph.D., is a professor of clinical stem cell research at Karolinska Institutet. Dr. Le Blanc received her MD from the Karolinska Institutet in 1993, and her Ph.D. in 1999, also from the Karolinska Institutet. In 2002 she became a certified specialist in hematology. She has mentored many trainees, Ph.D. students, and postdocs over the years. Dr. Le Blanc has published well over 100 peer-reviewed publications and review articles, been cited more than 12,000 times, and given some 140 presentations at various national and international meetings over the last 10 years. Dr. Le Blanc’s main research interest is mesenchymal stem cells, haematopoietic stem cell transplantation, and immunology. Dr. Le Blanc is a member of several international and national committees including notably the Nobel Assembly at Karolinska Institutet and The Royal Swedish Academy of Science. She is also a member of several advisory boards and has been responsible for the organization of several national and international scientific meetings, and also served on many program committees. She is the recipient of several awards including the Knut & Alice Wallenberg Foundation award for young female researchers, the Swedish Medical Society award for young scientists, and the Tobias Foundation Prize for the excellent studies of the immunological properties of mesenchymal stem cells and their use in mesenchymal stem cell therapy, awarded by the Royal Swedish Academy of Science.

Ruslan M. Medzhitov, Ph.D., is the Sterling Professor of Immunobiology at Yale University School of Medicine. He is interested in understanding biological processes and phenomena from first principles. Currently, Medzhitov and his team have several areas of focus: evolutionary medicine; biology of inflammation and its relation to physiology and homeostasis; mechanisms and functions of allergy; tissue biology; non-canonical functions of the immune system; and the logic of gene expression programs.

Erika Moore, Ph.D., is the Rhines Rising Star Assistant Professor in the Department of Materials Science and Engineering at the University of Florida. She earned her Ph.D. in biomedical engineering from Duke University in 2018 and her bachelor’s degree in biomedical engineering from the Johns Hopkins University in 2013. Under the guidance of Dr. Jennifer L. West, Moore’s doctoral thesis focused on the use of macrophages, innate immune cells, to support vascularized engineered tissue. She was awarded the Outstanding Doctoral Dissertation Award from Duke University for this work. Dr. Moore was the Provost’s Postdoctoral Fellow and a visiting professor at the Johns Hopkins University in the Department of Biomedical Engineering until June 2020. Ongoing research efforts of the Moore Lab seek to understand how immune cells can be leveraged to enhance tissue regeneration, develop materials capable of directing immune cells towards desired clinical outcomes, and create in vitro tissue models to profile immune cell–blood vessel interactions in clinically relevant disease settings. Her lab is especially interested in applications for the autoimmune disorder lupus, which disproportionately affects Black women. Recently acknowledged as Forbes 30 Under 30 in the health care category, Dr. Moore is a former trustee on the Duke Board of Trustees. She has been awarded a KL2 NIH Training grant through the UF Clinical and Translational Science Institute, a Space Research Initiative grant, the NSF Graduate Research Fellowship, and a Ford Foundation Fellowship.

Garry Nolan, Ph.D., is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF- B p65/RelA and the development of rapid retroviral production systems). He has published over 300 research articles and is the holder of 40 U.S. patents, and has been honored as one of the top 25 inventors at Stanford University. Dr. Nolan is a member of the Parker Institute for Cancer Immunotherapy at Stanford. His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan’s recent efforts are focused on a single-cell analysis advance using a mass spectrometry-flow cytometry hybrid device (CyTOF) and nanoscale imaging with the “Multiparameter Ion Beam Imager” (MIBI). Further developments in imaging are enabled by CODEX—a system that inexpensively converts fluorescence scopes into high-dimensional imaging platforms. Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense, the first recipient of an FDA BAAA for “Bio-agent protection” from the FDA for a “Cross-Species Immune System Reference,” and received the award for “Outstanding Research Achievement in 2011” from

the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan is an outspoken proponent of translating public investment in basic research to serve the public welfare. He has founded or cofounded several companies (Rigel Inc., Nodality Inc., BINA, Apprise, Ionpath, Akoya.) He also serves on the boards of directors of several companies and consults for other biotechnology companies.

Michel Sadelain, M.D., Ph.D., is the founding director of the Center for Cell Engineering and head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center, where he holds the Stephen and Barbara Friedman Chair. He is also a member of the departments of Medicine and Pediatrics at Memorial Hospital and the molecular pharmacology and chemistry program of the Sloan Kettering Institute. Dr. Sadelain’s research focuses on human cell engineering and cell therapy to treat cancer and hereditary blood disorders. He and his laboratory have made major contributions to the field of chimeric antigen receptors (CARs). His group was the first to report the design of “second-generation” CARs in 2002. In addition, the Sadelain Laboratory developed artificial antigen presenting cells, auto- and trans-costimulatory engineering strategies, combinatorial antigen approaches, and inhibitory CARs; his group was first to publish dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with CD19-targeted T cells.

Dr. Sadelain received his MD from the University of Paris, France, in 1984 and his Ph.D. from the University of Alberta, Canada, in 1989. After completing a clinical residency at the Centre Hospitalier Universitaire Saint-Antoine in Paris, Dr. Sadelain carried out a postdoctoral fellowship with Richard Mulligan, Ph.D., at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, before joining Memorial Sloan Kettering in 1994 as an assistant member. Dr. Sadelain is a member of the American Society of Cell and Gene Therapy, where he served on the board of directors from 2004 to 2007, and is an elected member of the American Society for Clinical Investigation. He has authored more than 150 scientific papers and book chapters. Dr. Sadelain holds 13 patents in immunotherapy and received the 2012 William B. Coley Award for Distinguished Research in Tumor Immunology.

Kaitlyn Sadtler, Ph.D., is an Earl Stadtman Tenure-Track Investigator and the chief of the Section for Immunoengineering at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health. Her research focuses on how the tissue microenvironment changes a host response to regenerative scaffolds used in tissue engineering and how to manipulate that environment to promote tissue growth and

regeneration. Dr. Sadtler has also lent her lab’s expertise to the fight against COVID-19, launching the NIH Serologic Survey to determine the number of undiagnosed infections of SARS-CoV-2 in the United States via remote blood sampling and antibody testing. Prior to beginning her lab at NIBIB, Sadtler completed a postdoctoral fellowship at the Massachusetts Institute of Technology in the Department of Chemical Engineering. There, she was awarded a Ruth L. Kirschstein Postdoctoral Fellowship for her work on immunology and tissue engineering. Dr. Sadtler was listed on BioSpace’s 10 Life Science Innovators Under 40 To Watch and StemCell Tech’s Six Immunologists and Science Communicators to Follow. She was recognized as a 2018 TED Fellow and delivered a TED talk that has been viewed over 2.4 million times and was listed as one of the top-viewed talks of 2018. Dr. Sadtler was selected for the 2019 Forbes 30 Under 30 List in Science and as a 2020 TEDMED Research Scholar. Dr. Sadtler received her Ph.D. from the Johns Hopkins University School of Medicine, where her thesis research was published in Science magazine, Nature Methods, and others.

Sonja Schrepfer, M.D., Ph.D., is a professor at the University of California San Francisco (UCSF), Gladstone-UCSF Institute of Genomic Immunology, and a Scientific Founder and SVP (Head of the Hypoimmune Platform) of Sana Biotechnology, Inc. Dr. Schrepfer is the founder and director of the Transplant and Stem Cell Immunobiology (TSI) Lab. Work by Dr. Sonja Schrepfer is at the forefront of stem immunobiology and paves the way for treatment of a wide range of diseases—from supporting functional recovery of failing myocardium to the derivation of other cell types to treat diabetes, blindness, cancer, lung, neurodegenerative, and related diseases. Her work demonstrates that protecting transplanted cells from immune rejection is the key to unlocking the potential of regenerative medicine. Before pursuing a career as a research scientist, Dr. Schrepfer was trained in cardiac surgery and heart/lung transplantation and was a resident in the Cardiothoracic Surgery Departments in Munich and Hamburg, Germany. She received her Ph.D. in transplant immunology from the University of Hamburg. Dr. Schrepfer’s findings have been published in leading journals such as Nature and Science and she has received numerous awards, such as the prestigious DFG-Heisenberg professorship (2009), the Innovation Award from Academia (Germany, 2014), the science award from the German Academy of Sciences (Leopoldina, 2015), and the Galenus-von-Pergamon Medal in Basic Medical Sciences (2019).

Charles N. Serhan, Ph.D., DSc, is the Gelman Professor at Harvard Medical School and codirector of Brigham Research Institute. His lab focuses on structural elucidation of molecules and pathways that activate resolution of inflammation. He is PI/PD of Program Project “Resolution Mechanisms

in Acute Inflammation: Resolution Pharmacology” (P01-GM095467). Dr. Serhan has over 25 years of experience leading multidisciplinary research teams and led as Principle Investigator/Program Director Program (PI/PD) Project “Molecular Mechanisms in Leukocyte-Mediated Tissue Injury” (P01-DE13499) and was PI/PD for “Specialized Center for Oral Inflammation and Resolution” (P50-DE016191). Importantly, he is hands on at the bench and has trained over 60 fellows and trainees that have successful careers in academic medicine and industry.

Megan Sykes, M.D., is the Michael J. Friedlander Professor of Medicine and professor of microbiology & immunology and surgical sciences (in surgery) at Columbia University. She is the founding director of the Columbia Center for Translational Immunology (CCTI) at Columbia University, director of research for the Transplant Initiative at Columbia University Medical Center (CUMC) and director of bone marrow transplantation research, Division of Hematology/Oncology at CUMC. Dr. Sykes completed her M.D. training at the University of Toronto in 1982, after which she completed a medical residency, then moved to the National Institutes of Health, Bethesda, Maryland, in 1985 as a Fogarty Visiting Associate. She joined the Massachusetts General Hospital and Harvard Medical School as an assistant professor in 1990 and was tenured as a full professor in 1999, then named to the Harold and Ellen Danser Chair in Surgery. She moved to Columbia University in 2010 to establish the CCTI, which now includes a thriving preclinical transplant program and a staff of 115 people including 19 faculty members; 16 laboratory programs in transplantation, autoimmune disease, infection, and cancer immunology; and six core facilities.

Dr. Sykes introduced the idea that graft-versus-leukemia/lymphoma effects could be separated from graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT) by allowing GVH-reactive T cells to expand while preventing migration to the epithelial GVHD target tissues. She showed that inflammation was a critical checkpoint for such migration, which was avoided when GVH-reactive T cells were administered after conditioning-induced inflammation had subsided in mixed chimeras. These studies led to clinical trials of nonmyeloablative haploidentical HCT that achieved mixed chimerism across human leukocyte antigen (HLA) barriers without GVHD. These results paved the way for the first clinical trials of mixed chimerism that achieved renal allograft tolerance across HLA barriers. Dr. Sykes dissected the role of intrathymic and peripheral tolerance mechanisms and pioneered minimal conditioning approaches for using HCT to achieve allograft and xenograft tolerance. Her work demonstrated that (and identified mechanisms by which) mixed chimerism achieves natural antibody-producing B-cell tolerance and natural killer (NK)-cell tolerance in addition to T-cell tolerance. She developed a method of tracking the

alloreactive T-cell repertoire in human transplant recipients and has used it along with other techniques to understand T-lymphocyte dynamics in the graft and the periphery of human transplant recipients. This work led to the discovery of hematopoietic progenitors in the human intestinal mucosa and demonstration of their turnover from a circulating pool in human intestinal allograft recipients. She has pioneered the development and use of humanized mouse models for the study of type 1 diabetes and for xenograft tolerance induction. Her work on xenogeneic thymic transplantation for tolerance induction led, for the first time, to long-term kidney xenograft survival in nonhuman primates.

Dr. Sykes has published more than 473 papers and chapters describing her work. She has served on the Transplantation Society (TTS) Council and has been president of the International Xenotransplantation Association (IXA) and vice president of TTS. She has received many honors and awards, including the Wyeth-Ayerst Young Investigator Award from the American Society of Transplant Physicians (1998), the AST Basic Science Established Investigator Award (2007), the TTS Roche Award for Outstanding Achievement in Transplantation Science (Basic) (2010), the TTS Award for Outstanding Achievement in Transplantation (Basic Science) (2014), and the 2018 Medawar Prize. She is a member of the Association of American Physicians, a distinguished fellow of the American Association of Immunologists, a fellow of the American Association for the Advancement of Science, and an honorary member of IXA. She was inducted into the Institute of Medicine of the National Academies (now the National Academy of Medicine) in 2009. Dr. Sykes is president-elect of the Federation of Clinical Immunology Societies (FOCIS).

Bob Valamehr, Ph.D., is the chief research and development officer at Fate Therapeutics, overseeing the company’s research and development activities. Previously, Dr. Valamehr has held the positions of chief development officer and vice president of cancer immunotherapy at Fate Therapeutics. Prior to that, he played key scientific roles at Amgen, the Center for Cell Control (an NIH Nanomedicine Development Center), and the Broad Stem Cell Research Center, developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis, and to better understand cellular signaling pathways associated with cancer. He has coauthored numerous studies and patents related to stem cell biology, oncology, and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), his MBA from Pepperdine University, and his BS from the Department of Chemistry and Biochemistry at UCLA.

Thomas Wynn, Ph.D., is the vice president of discovery in the Inflammation and Immunology Research Unit at Pfizer and director of Pfizer’s postdoctoral training program. He currently leads Pfizer’s discovery efforts in the areas of immune tolerance, epithelial cell biology, immunometabolism, innate immunity, and fibrosis. Dr. Wynn is a recognized expert on immunology and fibrosis who spent 26 years at the National Institutes of Health, most recently as a senior investigator and chief of the Immunopathogenesis Section of the Laboratory of Parasitic Disease, in the National Institute of Allergy and Infectious Diseases. He received his Ph.D. from the Department of Medical Microbiology and Immunology at the University of Wisconsin in Madison, Wisconsin and has published more than 200 research papers, reviews, and book chapters in many prestigious journals such as Nature, Science, and Nature Immunology. Dr. Wynn has been included on the Thomson Reuters list of Highly Cited Researchers due to his important contributions to understanding the role of cytokines and growth factors in the progression and resolution of chronic inflammation, tissue regeneration, and fibrosis.

This page intentionally left blank.